A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 3973
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LMWH
Long Form : low molecular weight heparin
No. Year Title Co-occurring Abbreviation
2021 "Part of the Ritual": Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome. ---
2021 'Wandering spleen with acute torsion' : a rare indication for splenectomy in an adult, complicated by postoperative splanchnic venous thrombosis and intestinal gangrene. WS
2021 A botanical medicine dragon's blood exhibited clinical antithrombosis efficacy similar to low molecular weight heparin. DD, DVT, FDP
2021 A case report of arterial and venous thromboembolism in a patient with severe COVID-19 pneumonia. COVID-19
2021 A Distinctive Approach to Venous Thromboembolism Treatment in a Pediatric, Hemodialysis Patient: A Case Report. HD, UFH
2021 A Tale of Two Centers: Is Low-Molecular-Weight Heparin Really Superior for Prevention of Post-Traumatic Venous Thromboembolism? DVT, PE, UFH, VTE
2021 A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation. CI
2021 Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer. tPA, uPA
2021 American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. ASH, DOAC, GRADE, VTE
10  2021 Anticoagulant management by low-dose of low molecular weight heparin in patients with nonvalvular atrial fibrillation following hemorrhagic transformation and complicated with venous thrombosis: Five case reports and literature review. HI, HT, NVAF
11  2021 Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. AF, DOACs
12  2021 Anticoagulation strategies in continuous renal replacement therapy. CRRT, KDIGO, RCA, UFH
13  2021 Antithrombotic prophylaxis in children and adolescents' patients with SARS-CoV-2 (COVID-19) infection: A practical guidance for clinicians. COVID-19, VTE
14  2021 Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence? CI, RR, UFH
15  2021 Aortic thrombosis in COVID-19. ---
16  2021 Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy. HR, VTE
17  2021 Case Report: Spontaneous Intramural Hematoma of the Colon Secondary to Low Molecular Weight Heparin Therapy. CT
18  2021 Cellular Immune Response to COVID-19 and Potential Immune Modulators. COVID-19, IFN, IVIG, SARS-CoV-2
19  2021 Cerebrovascular manifestations in hematological diseases: an update. CVT, PNH, TTP
20  2021 Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection. ---
21  2021 Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism. CAT, DOAC
22  2021 Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns. ACE2, COVID-19, NSAIDs, SARS-CoV-2
23  2021 Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. ARDS, COVID-19
24  2021 Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. ICU, ISTH-SSC, ULN
25  2021 Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study. CAT, LC, VTE
26  2021 Current status of treatment of cancer-associated venous thromboembolism. DOACs, VTE
27  2021 Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management. DIC, VTE
28  2021 Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol. DASH-TOP, VTE
29  2021 Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review. COVID-19, DIC, ISTH, SIC, UFH
30  2021 Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma. DOACs, GBM, ICH, OS, PE
31  2021 Double Blind Pilot Randomized Trial Comparing Extended Anticoagulation to Placebo Following Major Lung Resection for Cancer. DVT, PE, RCT, VTE
32  2021 E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. s.c
33  2021 Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. DH, HR
34  2021 Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial. IUGR, PE
35  2021 Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: A double blind placebo controlled multicenter study. ICH, VTE
36  2021 Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. IPTW, MB, VTE
37  2021 Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. CIs, DOACs, HRs, VTE
38  2021 Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis. CIs, ORs, PVT
39  2021 Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis. DOAC, ISTH, OR, VKA, VTE
40  2021 Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature. NOAC, VTE
41  2021 Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered? COVID-19
42  2021 Feasibility of anticoagulation using low molecular-weight heparin during catheter-directed thrombolysis for lower extremity deep venous thrombosis. CDT, DVT, sub-TPDA, TPDA
43  2021 Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study. DVT, ICU
44  2021 Fondaparinux Pre-, Peri-, and/or Postpartum for the Prophylaxis/Treatment of Venous Thromboembolism (FondaPPP). VTE
45  2021 Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit. anti-Xa, APTT, ICU, UFH
46  2021 Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study. COVID-19, UFH
47  2021 Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis. ACLF, TAT, UFH, VTE
48  2021 Impact of Pharmaceutical Prophylaxis on Radiation-Induced Liver Disease Following Radioembolization. MP, PTX, RE, RILD, SP, UDCA
49  2021 Incidence and risk factors associated with venous thromboembolism following primary total hip arthroplasty in low-risk patients when using aspirin for prophylaxis. DVT, OR, PE, THR, VTE
50  2021 Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics. ---
51  2021 Is COVID-19 an Independent Risk Factor for Heparin-Induced Thrombocytopenia? HIT, SARS-CoV-2, WHO
52  2021 Isolated Radial Vein Thrombosis: Upper Extremity Deep Vein Thrombosis in a Patient With COVID-19 Infection. COVID-19, DOAC, DVT
53  2021 Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. DVT
54  2021 Low Molecular Weight Heparin in Liver Transplant Recipients After Sleeve Gastrectomy. DVT, PE, PV, SG
55  2021 Low-molecular-weight heparin calcium attenuates the tourniquet-induced ischemia-reperfusion injury in rats. IRI, SD
56  2021 Low-molecular-weight heparin versus unfractionated heparin in pediatric traumatic brain injury. PSM, TBI, UH, VTE
57  2021 Management of Patients Receiving Direct Oral Anticoagulants Scheduled for Radical Prostatectomy: An Update of a Prospective Assessment. DOAC, DOACs, RP
58  2021 Massive pulmonary embolism presenting with hemoptysis and S1Q3T3 ECG findings. ---
59  2021 Mechanical heart valve thrombosis during pregnancy under non-warfarin anticoagulation therapy: Two-case report and literature review. anti-Xa, MHV, MVT, VKA
60  2021 Multiple arterial and venous thromboembolism in a male patient with hereditary protein C deficiency: A case report. CTA, NOACs, PROC
61  2021 NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes. ---
62  2021 New-Onset Atrial Fibrillation and Multiple Systemic Emboli in a COVID-19 Patient. AF, COVID-19, DOAC, DVT, PE, SARS-CoV-2, VTE
63  2021 Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO). ABI, hs-CRP, TAO
64  2021 Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis. CIs, FGR, LDA, NetMA, ORs
65  2021 Point of care ultrasound (POCUS) in diagnosis of proximal deep vein thrombosis among COVID-19 hospitalized patients with a high rate of low molecular weight heparin prophylaxis. DVT, ICU, PE, POCUS
66  2021 Portal vein thrombosis: A concise review (Review). PVT
67  2021 Porto-mesenteric vein thrombosis after laparoscopic sleeve gastrectomy. A case report. LSG, PMVT
68  2021 Postoperative Low Molecular Weight Heparin-induced Infection in Gastrointestinal Cancer Patients. A 2-year Single Centre Experience. ---
69  2021 Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries. GCS, IPC, LMICs, UFH, VTE
70  2021 Prevalence of Venous Thromboembolism Following Acute Spinal Cord Injury in an Urban Inner City Hospital. SCI, VTE
71  2021 PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients. PE, VTE
72  2021 Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: A systematic review and network meta-analysis. CI, RCTs, RR, SCD, VTE
73  2021 Prophylactic anticoagulation for preterm premature rupture of membranes: a decision analysis. PPH, PPROM, UFH
74  2021 Pulmonary thromboembolism in coronavirus disease 2019 patients undergoing thromboprophylaxis. COVID-19, CTPA, IQR, LL-US, PTE
75  2021 Regional citrate anticoagulation versus low molecular weight heparin for CRRT in hyperlactatemia patients: A retrospective case-control study. CRRT, RCA
76  2021 Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada. CAT, DOACs, VTE
77  2021 Right neck venous thrombosis following ovarian hyperstimulation syndrome in a patient with protein S deficiency: A case report and review of literature. ART, OHSS
78  2021 Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. ALL, ASNase, DFCI, PMCC, VTE
79  2021 Risk-Stratified Venous Thromboembolism Prophylaxis after Total Joint Arthroplasty: Low Molecular Weight Heparins and Sequential Aspirin vs Aggressive Chemoprophylaxis. TJA, VTE
80  2021 Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial. PVST
81  2021 Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies. DOACs, ICH
82  2021 Safety profile of preoperative administration of low-molecular-weight heparin on minimally invasive lung cancer surgery: a randomized controlled trial. POL, PRL
83  2021 Secondary Anticoagulation Prophylaxis for Catheter-Related Thrombosis in Pediatric Intestinal Failure: Comparison of Short- Vs Long-Term Treatment Protocols. CRT, IF, PN
84  2021 Shield and sword nano-soldiers ameliorate rheumatoid arthritis by multi-stage manipulation of neutrophils. CIA, LT NPs, RA, TOS
85  2021 Size- and charge-dependent modulation of the lytic susceptibility and mechanical stability of fibrin-histone clots by heparin and polyphosphate variants. NETs
86  2021 Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia. RBCs, S-NACH, SCD, UFH
87  2021 Suppression of Hypoxia-Inducible Factor 1α by Low-Molecular-Weight Heparin Mitigates Ventilation-Induced Diaphragm Dysfunction in a Murine Endotoxemia Model. HIF-1alpha, MV, VIDD
88  2021 Survival of patients with cancer associated thrombosis at the Uganda Cancer Institute. CAT, OS, UCI, UGI, VTE
89  2021 The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19. CHD, OR
90  2021 The effect of the transition to Electronic Patient Records on adherence to venous thromboembolism prophylaxis guidelines in general surgical patients. EPR, TEDs, VTEs
91  2021 The effectiveness and safety of LMWH for preventing thrombosis in patients with spinal cord injury: a meta-analysis. UFH
92  2021 The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis. CAT, CRNMB, MB, NCB, RR, VTE
93  2021 The role of low molecular weight heparin on recurrent pregnancy loss: A systematic review and meta-analysis. CI, RCTs, RPL, RRs
94  2021 The safety and effectiveness of salvianolate in preventing perioperative venous thromboembolism in China: A PRISMA-compliant meta-analysis based on RCTs. D-D, DVT, FIB, PLT, PT, RCTs, VTE, WBHSV, WBLSV
95  2021 Therapeutic effect of low-molecular-weight heparin on adult sepsis: a meta-analysis. CI, MD, MODS, RR
96  2021 Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders. ---
97  2021 Thromboprophylaxis for orthopedic surgery; An updated meta-analysis. DOACs, DVT, PE, RCTs, VTE
98  2021 Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review. ARDS, COVID, tPA
99  2021 Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. DOACs, VTE
100  2021 Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. ATE, COVID-19, CrCl, DD, ICU, UFH, VTE